Serono Rebif: 80% Of Rxs Are Switches, Efficacy Is Main Marketing Message
Executive Summary
Eighty percent of Rebif prescriptions are switches away from other multiple sclerosis therapies, Serono VP-Neurology Corporate Marketing Samar Shah, MD, said during Serono's R&D day in London Dec. 2